"Low-dose naltrexone (LDN) failed to outperform placebo in reducing pain or improving secondary outcomes in women with fibromyalgia, according to data presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Annual Meeting."
www.medscape.com/s/viewarticl...
Low-dose naltrexone does not provide real clinical benefit for patients with fibromyalgia compared to placebo, according to a clinical trial.
